Grail (NASDAQ:GRAL) Coverage Initiated at Wolfe Research

Wolfe Research assumed coverage on shares of Grail (NASDAQ:GRAL) in a report issued on Friday, Marketbeat.com reports. The brokerage set a “peer perform” rating on the stock.

Separately, Guggenheim assumed coverage on Grail in a research report on Thursday, October 17th. They issued a “neutral” rating for the company.

Grail Price Performance

Shares of NASDAQ:GRAL opened at $14.80 on Friday. The firm has a 50-day moving average price of $13.82. Grail has a 52-week low of $12.33 and a 52-week high of $23.36.

Insider Activity

In other news, CEO Robert P. Ragusa sold 123,454 shares of the stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $14.02, for a total transaction of $1,730,825.08. Following the transaction, the chief executive officer now owns 612,661 shares in the company, valued at approximately $8,589,507.22. This trade represents a 16.77 % decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, major shareholder Chun R. Ding purchased 7,629 shares of Grail stock in a transaction that occurred on Tuesday, October 1st. The stock was purchased at an average price of $13.52 per share, with a total value of $103,144.08. Following the completion of the purchase, the insider now directly owns 3,503,655 shares in the company, valued at $47,369,415.60. This trade represents a 0.22 % increase in their ownership of the stock. The disclosure for this purchase can be found here. Insiders have purchased 58,829 shares of company stock valued at $757,298 over the last ninety days.

About Grail

GRAIL, Inc, a biotechnology company, focuses on developing technologies for early cancer detection. The company develops Galleri, a screening test for asymptomatic individuals over 50 years of age; and DAC, a diagnostic aid for cancer tests to accelerate diagnostic resolution for patients for whom there is a clinical suspicion of cancer.